EVLV reports Q1 2026 results today against a backdrop of persistent insider selling — a pattern that has run for months and now sits directly in the market's line of sight.
Founder and Director Michael Ellenbogen has sold shares every month since at least March, offloading roughly 80,000–92,000 shares per tranche at prices ranging from $5.10 to $6.32. CFO George Kutsor followed suit in early May. The 90-day net insider position nets to a sale of approximately $2.27 million across the group. None of these are distress signals in isolation — awards and sells often run together under pre-set plans — but the consistency and frequency of Ellenbogen's activity, combined with the stock's 5% drop on Tuesday alone, gives the pattern more weight heading into today's report.
The short-selling community is not piling on, which is the notable divergence here. Short interest runs at roughly 4.6% of free float — meaningful but not extreme — and has actually edged down about 1.2% on the week. More telling is the lending market: availability is exceptionally loose at over 3,500%, meaning there is no shortage whatsoever of shares for new shorts to borrow. Borrowing costs at 0.79% are low and falling, down sharply over the past week. The borrow market is not pricing in stress. Options positioning tilts the same way: the put/call ratio at 0.19 is near the bottom of its 52-week range of 0.15–0.55, sitting slightly above its recent average but with only a modest z-score of 1.5. Call demand continues to dominate, which suggests options traders have not turned defensive.
The analyst community provides the clearest counterweight to the insider-selling narrative. Four buy-rated analysts cover the stock, with a consensus price target near $10 — roughly 78% above the current $5.62. TD Cowen reiterated its Buy and $10 target as recently as June 9, the day of the previous earnings event. The bull case rests on 29% revenue growth, a growing subscription model, and ~100 new system orders in recent quarters. Bears point to negative earnings — the trailing PE is deeply negative and EV/EBITDA near 56x — along with go-to-market execution risk and questions around historical revenue recognition. EPS surprise ranks in the 84th percentile historically, a genuinely strong track record, though near-term EPS momentum scores rank in the bottom 10% of the universe, suggesting estimate cuts have been running recently.
Two Sigma built a sizeable new position in Q1 (adding nearly 2.9 million shares), and Alyeska added over 2.4 million — both notable institutional entries that provide a floor of informed buying against the insider flow. Today's print will test whether Evolv's subscription transition is accelerating fast enough to justify the $10 analyst target and silence the steady drumbeat of selling from the people who built the company.
See the live data behind this article on ORTEX.
Open EVLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
